One more review of last December’s ASH in San Diego.

Earlier in the week I promised to write a bit about the exhibit areas you find at ASH and ASCO events.

I’m home from the hospital, feeling better and settling-in for what I hope turns-out to be a great 2012.

While I was at ASH in San Diego last December, I was looking for “under the radar” type salvage therapy options for myeloma patients who had become resistant (refractory) to Revlimid and/or Velcade.

OncologySTAT ran this feature article about pomalidomide last week in their hematology edition.  Here are a few excerpts:

One of our readers, Ed from California,  has had trouble posting comments.  Sorry about that, Ed!

The risk of developing a secondary cancer following years of ongoing treatment was a red-hot issue one year ago.

I don’t post a lot of information about MGUS and smoldering multiple myeloma on this site.

If your read Friday’s post about my emotional evening at the IMF’s International Jounalist event last week, you will probably recall how my roller-coaster “crashed down” after hearing about an unexpectedly short, 8 month overall survival (OS) benefit from using pomalidomid and dexamethasone after patients became refractory to Revlimid and Velcade.

Yes, I’ve been busy!

I featured a number of links to important new therapy related news from ASH over the past few days at MyelomaNews.com.

I left off yesterday, talking about how a promising Revlimid maintenance clinical trial that was otherwise tarnished by a lack of improvement in overall survival (OS) among patients in the study.

Here is information about Millennium’s new, oral proteasome inhibitor, MLN9708.  Looks like they are making good progress…

I just finished writing an article about Monday’s night International Myeloma Foundation’s Journalist Workshop.  I will provide a link to the article as soon as it runs on the IMF’s website.

Today was by far the most important day for multiple myeloma patients here at ASH.

I’m here at the American Society of Hematology (ASH) meetings in San Diego, blogging on behalf of the International Myeloma Foundation (IMF).

Last night I reported on lectures by the Mayo Clinic’s S. Vincent Rajkumar and Professor Jesus San-Miguel from Spain.

Good morning!  Time zones.  Who knew going from Florida to California would be such an adjustment!

As important and exciting as ASH can be, I am always disappointed by how little alternative medicine/supplement data is available.

Don’t forget to check MyelomaNews.com for updates leading up to this year’s American Society of Hematology (ASH) meetings in San Diego.